Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib and Necitumumab in EGFR+ NSCLC
NCT03054038Phase 1Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Jul 2017
- Primary completion
- Mar 2022
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of afatinib and necitumumab in non-small cell lung cancer (NSCLC), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jul 2017; status: terminated.
02
Drugs
afatinibnecitumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03054038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03054038.